companydata.dkcompanydata.dk

Novo Nordisk Pharmatech A/S: Financial statements 2018

CVR: 13246149

Source: annual report 2018, Danish Business Authority

01/01/2018 – 31/12/2018

Novo Nordisk Pharmatech A/S (CVR 13246149) has filed annual accounts for 2018. In 2018, the company reported revenue of DKK 690,700,000 and a net result of DKK 105,268,000 compared with DKK 103,665,000 the year before. That is an increase of 11% compared with the year before. The profit margin was 15.2%. Equity in the 2018 report amounted to DKK 614,221,000. The solvency ratio was 80.7%. The company had 170 employees in the financial year.

Revenue
DKK 690,700,000
Gross Profit
DKK 283,278,000
Profit/Loss
DKK 105,268,000
Equity
DKK 614,221,000
Total Assets
DKK 760,808,000
Employees
170

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2018690.7M283.3M105.3M614.2M170
2017622.4M263.4M103.7M529M163
2016669.1M238M87.4M468.3M158
2015505.2M228M92.1M400.9M150
2014495.2M176.6M55.3M336.8M150

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2018

Søren Thor Jensen joins the board of Novo Nordisk Pharmatech A/SNov 1, 2018

As of November 1, 2018, Søren Thor Jensen has joined the board of directors of Novo Nordisk Pharmatech A/S.

Ole Falvig Ramsby leaves the board of Novo Nordisk Pharmatech A/SNov 1, 2018

As of November 1, 2018, Ole Falvig Ramsby has left the board of directors of Novo Nordisk Pharmatech A/S.

Lars Sørensen leaves the board of Novo Nordisk Pharmatech A/SJun 30, 2018

As of June 30, 2018, Lars Sørensen has left the board of directors of Novo Nordisk Pharmatech A/S.

Novo Nordisk Pharmatech A/S: The 2017 annual report is outMay 17, 2018

Novo Nordisk Pharmatech A/S has published its annual report for 2017. Revenue came to DKK 622,436,000, and the net result was DKK 103,665,000.

About Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S is a Danish company of the type Aktieselskab based in Køge, founded in 1989. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named FEF CHEMICALS A/S and FERROSAN FINE CHEMICALS A/S. The management consists of Ulla Grove Krogsgaard Thomsen. The board consists of Mette Sofie Mørck Jarl (chair), Christian Brøgger Stolberg, Jacob Sten Petersen and Joachim Juel Hagemeister. The company is owned by NOVO NORDISK A/S. The company has 489 employees (2026). In 2025, the company reported revenue of DKK 1,041,584,000 and a net result of DKK 113,891,000 compared with DKK 60,619,000 the year before. Equity in the 2025 report amounted to DKK 2,441,318,000.

Source: annual report 2025, Danish Business Authority